College Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama out
As the current season in Ligue 1 unfolds, fans eagerly anticipate each match to see what magic this player will conjure next. Will he continue his goal-scoring spree and lead his team to glory? Only time will tell. One thing is for certain, though - the red devil has found his form and is ready to take on the challenges of the Champions League next year. Europe, brace yourselves, for the forgotten star is ready to shine bright once again.AP Sports SummaryBrief at 6:05 p.m. ESTAfter 9 Wins in 8 Consecutive Games, Guangsha Maintains the Top Spot with an Extremely Relaxed Schedule Ahead
As the homeowner now basks in the warmth of their home, they are reminded of the neighbor's "gift of warmth" and vow to pay it forward in their own way. This experience has not only brought two households closer together but has also sparked a ripple of kindness that has the power to spread far and wide.By MICHELLE L. PRICE and ROB GILLIES NEW YORK (AP) — President-elect Donald Trump’s recent dinner with Canadian Prime Minister Justin Trudeau and his visit to Paris for the reopening of the Notre Dame Cathedral were not just exercises in policy and diplomacy. They were also prime trolling opportunities for Trump. Related Articles National Politics | Trump names Andrew Ferguson as head of Federal Trade Commission to replace Lina Khan National Politics | Biden issues veto threat on bill expanding federal judiciary as partisan split emerges National Politics | Trump lawyers and aide hit with 10 additional felony charges in Wisconsin over 2020 fake electors National Politics | After withdrawing as attorney general nominee, Matt Gaetz lands a talk show on OANN television National Politics | What will happen to Social Security under Trump’s tax plan? Throughout his first term in the White House and during his campaign to return, Trump has spun out countless provocative, antagonizing and mocking statements. There were his belittling nicknames for political opponents, his impressions of other political figures and the plentiful memes he shared on social media. Now that’s he’s preparing to return to the Oval Office, Trump is back at it, and his trolling is attracting more attention — and eyerolls. On Sunday, Trump turned a photo of himself seated near a smiling first lady Jill Biden at the Notre Dame ceremony into a social media promo for his new perfume and cologne line, with the tag line, “A fragrance your enemies can’t resist!” The first lady’s office declined to comment. When Trudeau hastily flew to Florida to meet with Trump last month over the president-elect’s threat to impose a 25% tax on all Canadian products entering the U.S., the Republican tossed out the idea that Canada become the 51st U.S. state. The Canadians passed off the comment as a joke, but Trump has continued to play up the dig, including in a post Tuesday morning on his social media network referring to the prime minister as “Governor Justin Trudeau of the Great State of Canada.” After decades as an entertainer and tabloid fixture, Trump has a flair for the provocative that is aimed at attracting attention and, in his most recent incarnation as a politician, mobilizing fans. He has long relished poking at his opponents, both to demean and minimize them and to delight supporters who share his irreverent comments and posts widely online and cheer for them in person. Trump, to the joy of his fans, first publicly needled Canada on his social media network a week ago when he posted an AI-generated image that showed him standing on a mountain with a Canadian flag next to him and the caption “Oh Canada!” After his latest post, Canadian Immigration Minister Marc Miller said Tuesday: “It sounds like we’re living in a episode of South Park.” Trudeau said earlier this week that when it comes to Trump, “his approach will often be to challenge people, to destabilize a negotiating partner, to offer uncertainty and even sometimes a bit of chaos into the well established hallways of democracies and institutions and one of the most important things for us to do is not to freak out, not to panic.” Even Thanksgiving dinner isn’t a trolling-free zone for Trump’s adversaries. On Thanksgiving Day, Trump posted a movie clip from “National Lampoon’s Christmas Vacation” with President Joe Biden and other Democrats’ faces superimposed on the characters in a spoof of the turkey-carving scene. The video shows Trump appearing to explode out of the turkey in a swirl of purple sparks, with the former president stiffly dancing to one of his favorite songs, Village People’s “Y.M.C.A.” In his most recent presidential campaign, Trump mocked Florida Gov. Ron DeSantis, refusing to call his GOP primary opponent by his real name and instead dubbing him “Ron DeSanctimonious.” He added, for good measure, in a post on his Truth Social network: “I will never call Ron DeSanctimonious ‘Meatball’ Ron, as the Fake News is insisting I will.” As he campaigned against Biden, Trump taunted him in online posts and with comments and impressions at his rallies, deriding the president over his intellect, his walk, his golf game and even his beach body. After Vice President Kamala Harris took over Biden’s spot as the Democratic nominee, Trump repeatedly suggested she never worked at McDonalds while in college. Trump, true to form, turned his mocking into a spectacle by appearing at a Pennsylvania McDonalds in October, when he manned the fries station and held an impromptu news conference from the restaurant drive-thru. Trump’s team thinks people should get a sense of humor. “President Trump is a master at messaging and he’s always relatable to the average person, whereas many media members take themselves too seriously and have no concept of anything else other than suffering from Trump Derangement Syndrome,” said Steven Cheung, Trump’s communications director. “President Trump will Make America Great Again and we are getting back to a sense of optimism after a tumultuous four years.” Though both the Biden and Harris campaigns created and shared memes and launched other stunts to respond to Trump’s taunts, so far America’s neighbors to the north are not taking the bait. “I don’t think we should necessarily look on Truth Social for public policy,” Miller said. Gerald Butts, a former top adviser to Trudeau and a close friend, said Trump brought up the 51st state line to Trudeau repeatedly during Trump’s first term in office. “Oh God,” Butts said Tuesday, “At least a half dozen times.” “This is who he is and what he does. He’s trying to destabilize everybody and make people anxious,” Butts said. “He’s trying to get people on the defensive and anxious and therefore willing to do things they wouldn’t otherwise entertain if they had their wits about them. I don’t know why anybody is surprised by it.” Gillies reported from Toronto. Associated Press writer Darlene Superville contributed to this report.
By HALELUYA HADERO, Associated Press President-elect Donald Trump asked the Supreme Court on Friday to pause the potential TikTok ban from going into effect until his administration can pursue a “political resolution” to the issue. The request came as TikTok and the Biden administration filed opposing briefs to the court, in which the company argued the court should strike down a law that could ban the platform by Jan. 19 while the government emphasized its position that the statute is needed to eliminate a national security risk. “President Trump takes no position on the underlying merits of this dispute. Instead, he respectfully requests that the Court consider staying the Act’s deadline for divestment of January 19, 2025, while it considers the merits of this case,” said Trump’s amicus brief, which supported neither party in the case. The filings come ahead of oral arguments scheduled for Jan. 10 on whether the law, which requires TikTok to divest from its China-based parent company or face a ban, unlawfully restricts speech in violation of the First Amendment. Earlier this month, a panel of three federal judges on the U.S. Court of Appeals for the District of Columbia Circuit unanimously upheld the statute , leading TikTok to appeal the case to the Supreme Court. The brief from Trump said he opposes banning TikTok at this junction and “seeks the ability to resolve the issues at hand through political means once he takes office.”TikTok looks to block federal government’s shutdown order with court challenge
The journey to becoming the second Chinese player to start against Atletico Madrid is a testament to the dedication, perseverance, and hard work put in by this individual. It serves as a reminder of the sacrifices made, the obstacles overcome, and the dreams pursued in pursuit of excellence and success in the world of professional football. The road to success is never easy, but it is paved with determination, resilience, and unwavering commitment to one's craft.
So mark your calendars, book your tickets, and get ready for ten days of table tennis excellence at the WTT Grand Slam 2025 in Singapore. It's going to be a thrilling ride from start to finish, and you won't want to miss a single moment of the action.AMBCrypto CEO Jeevan Thomas on NFTs: Revolutionizing Digital Ownership 12-27-2024 10:00 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire The image symbolizes the transformative power of NFTs across digital art, gaming, and real estate, portraying the technological shift in ownership. NFTs are not just a trend; they represent a transformative shift in digital ownership, asserts Jeevan Thomas, CEO of AMBCrypto. From empowering artists with direct monetization to redefining industries like gaming and real estate, NFTs are unlocking unprecedented opportunities. In this article, Jeevan explores how NFTs are poised to revolutionize asset ownership and reshape the future. A Paradigm Shift in Ownership Imagine owning a piece of digital art, a virtual real estate plot, or an exclusive in-game item, all secured and authenticated through blockchain technology. This is the transformative promise of Non-Fungible Tokens (NFTs), which are redefining digital ownership across various industries. Jeevan Thomas [ https://www.linkedin.com/in/jeeevaan/ ], CEO of AMBCrypto [ https://ambcrypto.com/ ], a leading digital news publisher, emphasizes that NFTs are not just a fleeting trend but a fundamental shift in how we perceive and manage digital assets. What Are NFTs? NFTs are unique digital tokens that represent ownership of specific items or content on the blockchain. Unlike cryptocurrencies such as Bitcoin or Ethereum, which are fungible and can be exchanged on a one-to-one basis, NFTs are indivisible and unique. This makes them ideal for certifying ownership of digital assets like art, music, and virtual real estate. This uniqueness is at the heart of how NFTs are revolutionizing digital ownership. NFTs Empowering the Art World In the art world, NFTs have empowered artists to monetize their digital creations directly, eliminating the need for intermediaries. This direct-to-consumer model ensures that artists receive fair compensation for their work and retain control over their creations. Additionally, NFTs can be programmed with smart contracts to provide royalties to artists upon secondary sales, ensuring ongoing revenue as their work appreciates in value. Redefining the Music Industry The music industry is also experiencing a paradigm shift due to NFTs. Musicians can tokenize their work, offering fans exclusive ownership of songs, albums, or concert experiences. This not only creates new revenue streams but also fosters a deeper connection between artists and their audiences. Smart contracts embedded within NFTs ensure that artists receive a predetermined percentage of royalties upon secondary sales, providing transparency and fairness in revenue distribution. Transforming Gaming Experiences In gaming, NFTs are redefining player engagement by allowing true ownership of in-game assets. Players can purchase, sell, and trade items like skins, weapons, or virtual land across different platforms, creating real-world value from virtual experiences. This interoperability enhances the gaming experience and opens up new economic opportunities within virtual environments. Virtual Real Estate: A New Frontier Virtual real estate is another frontier being transformed by NFTs. Digital platforms like Decentraland allow users to purchase, develop, and monetize virtual land parcels. These virtual properties can be used for various purposes, including hosting events, creating virtual stores, or building digital art galleries, all secured through NFT ownership. Challenges and Concerns Environmental Impact Despite the excitement surrounding NFTs, challenges remain. Environmental concerns have been raised due to the energy-intensive nature of blockchain transactions, particularly on platforms like Ethereum. However, efforts are underway to develop more sustainable blockchain solutions to mitigate these impacts. Legal and Regulatory Issues Legal considerations also pose challenges, as the regulatory landscape for NFTs is still evolving. Issues such as copyright ownership, transfer of rights, and the legal status of NFTs in various jurisdictions are areas of ongoing debate and development. Clear legal frameworks are necessary to protect creators and consumers in the NFT ecosystem. Expanding Applications of NFTs Real Estate Tokenization Jeevan Thomas highlights that the potential applications of NFTs extend beyond art and entertainment. They can be utilized in sectors like real estate, where property deeds can be tokenized, providing a secure and transparent method for transferring ownership. This could streamline real estate transactions, reduce fraud, and increase accessibility to property investments. Identity and Credential Verification NFTs can also play a significant role in verifying identities and credentials. Academic degrees, professional certifications, and other credentials can be securely tokenized, preventing fraud and ensuring authenticity. This application could revolutionize how individuals and institutions manage and share verifiable information. The Future of Digital Ownership Jeevan Thomas believes that NFTs are not merely a technological innovation but a cultural and economic shift. They are democratizing access to ownership, enabling creators to gain fair value for their work, and providing consumers with a secure and transparent way to own digital assets. As the technology matures and regulatory frameworks solidify, the NFT ecosystem is poised to expand into new industries, offering unprecedented opportunities for creators, businesses, and consumers alike. NFTs are not just about owning digital assets-they are about redefining what ownership means in the digital age. Media Contact Company Name: AMBCrypto Contact Person: Sujeev Thomas Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=ambcrypto-ceo-jeevan-thomas-on-nfts-revolutionizing-digital-ownership ] Country: India Website: https://ambcrypto.com/ This release was published on openPR.
The match took place on August 14, 2020, in Lisbon, Portugal, as part of the revamped Champions League format due to the COVID-19 pandemic. Bayern Munich, under the guidance of Hansi Flick, were in scintillating form throughout the tournament, and Barcelona, despite their star-studded lineup including Lionel Messi, struggled to keep up with their German counterparts.Police are investigating a pair of shootings in Baltimore’s Southern District on Saturday afternoon. Around 2:30 p.m., officers responded to the 2100 block of West Patapsco Avenue for a report of a shooting and found a 25-year-old male suffering from injuries. The victim was transported to an area hospital where he is listed in stable condition, police said. Officers were then advised of a walk-in shooting victim at a nearby hospital and found a 27-year-old male suffering from apparent gunshot wounds. That victim is listed in critical condition. No other details have been released with either incident. Southern District detectives ask anyone with information to contact them at 410-396-2499 or Metro Crime Stoppers at 1-866-7Lockup
Wiley University celebrates Giving Tuesday, rallying support for futureSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 8, 2024-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy ® (polatuzumab vedotin-piiq) in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, December 7-10, 2024 in San Diego, California. This latest analysis conducted after a median follow-up of 60.9 months, includes descriptive data on primary and secondary endpoints, as well as safety results. “POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we are additionally encouraged by the five-year follow-up results,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “More than 38,000 people worldwide have been treated with Polivy in combination with R-CHP and these data continue to underscore its potential to improve outcomes for people diagnosed with this aggressive lymphoma.” Follow-up exploratory analysis after five-years indicated a positive trend in overall survival (OS) in the intent-to-treat (ITT) population in favor of Polivy in combination with R-CHP compared to Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Results showed a trend in reduction in the risk of death (HR 0.85; 95% CI: 0.63–1.15) for people with previously untreated DLBCL with the Polivy combination, an improvement on the three-year follow-up data (HR 0.94; 95% CI: 0.67–1.33). The five-year analysis of POLARIX indicates that the full difference in OS between treatment arms has yet to be observed and an additional two years of follow-up will continue. “Diffuse large B-cell lymphoma is a notoriously challenging cancer to treat, however, Polivy in combination with R-CHP has shown to be a critical advance for patients by helping to reduce relapse and disease progression,” said Gilles Salles, M.D., Ph.D., chief of Lymphoma Service, Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, New York. “The survival trend seen in this follow-up analysis reinforces the potential impact of frontline treatment with Polivy in combination with R-CHP and its role as a standard of care therapy.” In addition to the positive trend in OS, an observational analysis suggested nearly 25% fewer follow-up treatments such as radiation, systemic chemotherapy and CAR-T cell therapy were needed in patients receiving Polivy in combination with R-CHP compared to those treated with R-CHOP (38.3% versus 61.7%). At five years of follow-up, benefits in progression-free survival and disease-free survival with Polivy in combination with R-CHP were maintained, consistent with the three-year follow-up data, reinforcing the potential of Polivy in combination with R-CHP to provide durable and lasting remissions. The latest follow-up data also showed a numerical reduction in death related to patients’ lymphoma in those treated with Polivy in combination with R-CHP compared to those treated with R-CHOP (9.0% versus 11.4%). The safety profile remains consistent with the known profiles of the individual study medicines with no new safety signals observed, reinforcing the positive benefit-risk profile of this Polivy combination. Results from an expanded cohort of 1,000 patients including global and Chinese patients demonstrated comparability to the global ITT population. Polivy in combination with R-CHP is currently approved for the treatment of first-line (1L) DLBCL in more than 90 countries worldwide including the U.S., countries throughout the EU, the U.K., Japan, Canada and China. Genentech continues to work with health authorities around the world to bring this treatment regimen to even more patients. Genentech aims to offer various treatment options for DLBCL that meet the diverse needs of patients and healthcare systems. In an effort to elevate treatment standards even further, Genentech is exploring Polivy in combination with other molecules, including its bispecific antibodies. Studies include the Phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio ® (mosunetuzumab-axgb) in combination with intravenous (IV) Polivy versus IV Rituxan plus gemcitabine and oxaliplatin (R-GemOx) in second-line or later DLBCL, and the Phase III SKYGLO trial investigating the efficacy of Polivy in combination with R-CHP and Columvi ® (glofitamab-gxbm) versus Polivy in combination with R-CHP in 1L DLBCL. About the POLARIX Study POLARIX [ NCT03274492 ] is an international Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety and pharmacokinetics of Polivy ® (polatuzumab vedotin-piiq) plus Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) versus Rituxan, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Eight-hundred and seventy-nine patients were randomized 1:1 to receive either Polivy plus R-CHP plus a vincristine placebo for six cycles, followed by Rituxan for two cycles; or R-CHOP plus a Polivy placebo for six cycles, followed by two cycles of Rituxan. The primary outcome measure is progression-free survival as assessed by the investigator using the Lugano Response Criteria for malignant lymphoma. POLARIX is being conducted in collaboration with The Lymphoma Study Association (LYSA) and The Lymphoma Academic Research Organisation (LYSARC). About Diffuse Large B-Cell Lymphoma Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) blood cancer and is the most common form of non-Hodgkin’s lymphoma (NHL) in the U.S. While many people with DLBCL are responsive to treatment, the majority of those who relapse or are refractory to subsequent treatments have poor outcomes. DLBCL not otherwise specified is the most common category of large B-cell lymphoma (LBCL) and accounts for about 80% or more of cases. It applies to cases that do not fall into any specific disease subgroups of LBCL. About Polivy ® (polatuzumab vedotin-piiq) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL. Polivy U.S. Indication Polivy is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL). Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat DLBCL in adults who have progressed after at least 2 prior therapies. Important Safety Information Possible serious side effects Everyone reacts differently to Polivy therapy, so it’s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. Your doctor may stop or adjust your treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects. Side effects seen most often The most common side effects during treatment were Polivy may lower your red or white blood cell counts and increase uric acid levels. Polivy may not be for everyone. Talk to your doctor if you are These may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of Polivy treatment. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see the full Prescribing Information and visit https://www.Polivy.com for additional Important Safety Information. About Lunsumio ® (mosunetuzumab-axgb) Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development program for Lunsumio is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin’s lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, and other blood cancers. Lunsumio U.S. Indication Lunsumio (mosunetuzumab-axgb) is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer. It is not known if Lunsumio is safe and effective in children. The conditional approval of Lunsumio is based on response rate. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Lunsumio? Lunsumio may cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Lunsumio and can also be severe or life-threatening. Get medical help right away if you develop any signs or symptoms of CRS at any time, including: Due to the risk of CRS, you will receive Lunsumio on a “step-up dosing schedule.” Your healthcare provider will check you for CRS during treatment with Lunsumio and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Lunsumio, if you have severe side effects. What are the possible side effects of Lunsumio? Lunsumio may cause serious side effects, including: Your healthcare provider may temporarily stop or permanently stop treatment with Lunsumio if you develop severe side effects. The most common side effects of Lunsumio include: tiredness, rash, fever, and headache. The most common severe abnormal blood test results with Lunsumio include: decreased phosphate, increased glucose, and increased uric acid levels. Before receiving Lunsumio, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Lunsumio? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems. These are not all the possible side effects of Lunsumio. Talk to your healthcare provider for more information about the benefits and risks of Lunsumio. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects, as well as the Lunsumio full Prescribing Information and Medication Guide or visit https://www.Lunsumio.com . About Columvi ® (glofitamab-gxbm) Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is part of Genentech’s broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development program that also includes Lunsumio ® (mosunetuzumab), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Genentech is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma. Columvi U.S. Indication Columvi (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more prior treatments for their cancer. It is not known if Columvi is safe and effective in children. The conditional approval of Columvi is based on response rate and durability of response. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Columvi? Columvi can cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Columvi, and can also be serious and lead to death. Call your healthcare provider or get emergency medical help right away if you develop any signs or symptoms of CRS, including: Due to the risk of CRS, you will receive Columvi on a “step-up dosing schedule”. Your healthcare provider will monitor you for CRS during treatment with Columvi and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Columvi if you have severe side effects. Carry the Columvi Patient Wallet Card with you at all times and show it to all of your healthcare providers. The Columvi Patient Wallet Card lists the signs and symptoms of CRS you should get emergency medical help for right away. What are the possible side effects of Columvi? Columvi may cause serious side effects, including: The most common side effects of Columvi include: CRS, muscle and bone pain, rash, and tiredness. The most common severe abnormal lab test results with Columvi include: decreased white blood cells, decreased phosphate (an electrolyte), increased uric acid levels, and decreased fibrinogen (a protein that helps with blood clotting). Your healthcare provider may temporarily stop or completely stop treatment with Columvi if you develop certain side effects. Before receiving Columvi, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Columvi? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, shaking (tremors), sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of neurologic problems. These are not all the possible side effects of Columvi. Talk to your health care provider for more information about the benefits and risks of Columvi. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects , as well as the Columvi full Prescribing Information and Medication Guide or visit https://www.Columvi.com About Genentech in Hematology For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit http://www.gene.com/hematology . About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com . Dr. Salles has financial interests related to Roche and Genentech. View source version on businesswire.com : https://www.businesswire.com/news/home/20241208818007/en/ CONTACT: Media Contact: Kristen Ingram, (650) 467-6800Advocacy Contact: Catherine Creme Henry, (202) 258-8228Investor Contacts: Loren Kalm, (650) 225-3217 Bruno Eschli, 011 41 61 687 5284 KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY SOURCE: Genentech Copyright Business Wire 2024. PUB: 12/08/2024 12:30 PM/DISC: 12/08/2024 12:30 PM http://www.businesswire.com/news/home/20241208818007/enCollege Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama out
NoneSyrian government forces withdraw from central city of Homs as insurgent offensive acceleratesIn addition to the thrilling matches on the table, the WTT Grand Slam 2025 will also feature a range of exciting off-court activities and entertainment options for fans of all ages. From meet-and-greet sessions with the players to interactive fan zones and autograph signings, there will be plenty of opportunities for fans to get up close and personal with their favorite athletes.
In wake of officer's death, West Yellowstone police offer aid for those grieving
AP News Summary at 6:21 p.m. EST
In the aftermath of the match, Setien faced intense criticism from fans, pundits, and former players, many of whom questioned his ability to manage a team of Barcelona's stature. The defeat highlighted deeper issues within the club, including boardroom turmoil, player unrest, and an aging squad in need of rejuvenation.ALTOONA, Pa. — The suspect in the killing of UnitedHealthcare’s CEO struggled with deputies and shouted Tuesday while arriving for a court appearance in Pennsylvania, a day after he was arrested at a McDonald’s and charged with murder. Luigi Nicholas Mangione emerged from a patrol car, spun toward reporters and shouted something partly unintelligible referring to an “insult to the intelligence of the American people” while deputies pushed him inside. Prosecutors began to take steps to bring Mangione back to New York to face a murder charge while new details emerged about his life and how he was captured. The 26-year-old Ivy League graduate from a prominent Maryland real estate family was charged with murder hours after he was arrested in the Manhattan killing of Brian Thompson, who led the United States’ largest medical insurance company. At the brief hearing, defense lawyer Thomas Dickey informed the court that Mangione would not waive extradition to New York but instead wants a hearing on the issue. He has 14 days to challenge detention. Mangione likely was motivated by his anger with what he called “parasitic” health insurance companies and a disdain for corporate greed, a law enforcement bulletin obtained by The Associated Press said. He wrote that the U.S. has the most expensive health care system in the world and that profits of major corporations continue to increase while “our life expectancy” does not, according to the bulletin, based on a review of his hand-written notes and social media posts. Mangione called “Unabomber” Ted Kaczynski a “political revolutionary” and may have found inspiration from the man who carried out a series of bombings while railing against modern society and technology, according to the bulletin. Mangione remained jailed in Pennsylvania, where he was initially charged with possession of an unlicensed firearm, forgery and providing false identification to police. Manhattan prosecutors obtained an arrest warrant, a step that could help expedite his extradition from Pennsylvania. Mangione was arrested Monday in Altoona, Pennsylvania — about 230 miles west of New York City — after a McDonald’s customer recognized him and notified an employee, authorities said. Thompson, 50, was killed Wednesday as he walked alone to a Manhattan hotel for an investor conference. Police saw the shooting as a targeted attack. Get local news delivered to your inbox!
Wu Yingjie, once a prominent figure in Chinese politics, has found himself at the center of a corruption scandal that has rocked the country. Accused of abusing his power for personal gain, Wu is facing serious consequences for his actions.Match 1: Liverpool vs. AC Milan